GLPwatch
Papers (12034)
Page 117 of 201, ranked by citation count.
- Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.
- Reno-protective effects of GLP-1 receptor agonist and anti-platelets in experimentally induced diabetic kidney disease in male albino rats.
- Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid.
- Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart.
- BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
- NICE recommendations on tirzepatide for weight loss could increase NHS access.
- Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.
- Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes.
- Semaglutide (Wegovy) for the Treatment of Obesity.
- A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes.
- Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand.
- Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study.
- A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.
- Semaglutide Improved Cardiovascular Health in People Without Diabetes.
- Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study.
- Down-regulation of zinc transporter 8 in the pancreas of db/db mice is rescued by Exendin-4 administration.
- Qualitative and Quantitative Analyses of Noninvasive Diagnosis of Insulinoma Using [18F]FB(ePEG12)12-Exendin-4 PET/CT.
- The impact of glucagon and exenatide on oxidative stress levels and antioxidative enzyme expression in in vitro induced steatosis in HepG2 cell culture.
- Dulaglutide Alleviates Alzheimer's Disease by Regulating Microglial Polarization and Neurogenic Activity.
- Effect of the glucagon-like peptide-1 receptor agonists dulaglutide on kidney outcomes in db/db mice.
- Direct suppression of human islet dedifferentiation, progenitor genes, but not epithelial to mesenchymal transition by liraglutide.
- Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline.
- Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes. Reply.
- A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure.
- Cardiovascular Outcomes of New Medications for Type 2 Diabetes.
- Tirzepatide vs. Semaglutide for Obesity Treatment. Reply.
- Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.
- Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis.
- Interaction of Semaglutide and Ziprasidone in a Patient With Schizophrenia: A Case Report.
- Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes.
- GLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management.
- Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study.
- Effects of liraglutide on sperm characteristics and fertilization potential following experimentally induced diabetes in mice.
- Glucagon-Like Peptide-1 Use and Healthcare Resource Utilization for Depression and Anxiety Among Adults with Type 2 Diabetes: 2019 to 2023.
- Acute Pancreatitis Caused by Tirzepatide.
- What to Know About the New Semaglutide Pill for Obesity.
- Tirzepatide to treat obesity: phase III results.
- Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.
- Testicular cytoprotective effect of glucagon like peptide-1 in diabetic rats involves inhibition of apoptosis, endoplasmic reticulum stress and activation of autophagy.
- Effects of insulin and the glucagon-like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice.
- Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial.
- Advances in the management of obesity and heart failure: latest evidence from clinical trials.
- Assessment of Exenatide loaded Biotinylated Trimethylated Chitosan/HP- 55 Nanoparticles.
- Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.
- Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study.
- Semaglutide use for decreasing hidradenitis suppurativa resource utilization: A retrospective cohort study utilizing TriNetX.
- Obesity Epidemic: Pharmaceutical Weight Loss.
- Evaluating Weight Loss With Semaglutide in Elderly Patients With Type II Diabetes.
- Analysis of clinical studies on clozapine from 2012-2022.
- Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos.
- Liraglutide in heart failure: caution is needed.
- The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
- Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
- Tirzepatide, a novel, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist for the ongoing diabesity epidemic: the dawn of a new era?
- Association of semaglutide with retained gastric contents on endoscopy: Retrospective analysis.
- Role of LRP5/6/GSK-3β/β-catenin in the differences in exenatide- and insulin-promoted T2D osteogenesis and osteomodulation.
- A genetic screen identifies Crat as a regulator of pancreatic beta-cell insulin secretion.
- Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health.
- Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.
- Tackling Cravings in Medical Weight Management: An Update on Pathophysiology and an Integrated Approach to Treatment.